Stacking the Odds in Alzheimer’s Disease Drug Development

SysQuant® Global Phosphoproteomics

Goal – Establish the mechanism of action of two orally available, brain-penetrant small molecule inhibitors of casein kinase 1 delta that improved cognition in a rodent tauopathy model.

Outcome – Confirmation that many tau phosphorylation sites are reduced by drug treatment, as well as significant regulation of pathways demonstrated to involved in phospho-tau dependent disease mechanisms.

View all case studies